Details

Autor(en) / Beteiligte

• Abdullahi, Sa'ad T.
• Olagunju, Adeniyi
• Soyinka, Julius O.
• Bolarinwa, Rahman A.
• Olarewaju, Olusola J.
• Bakare‐Odunola, Moji T.
• Owen, Andrew
• Khoo, Saye

Titel

Pharmacogenetics of artemether‐lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?

Ist Teil von

• British journal of clinical pharmacology, 2019-03, Vol.85 (3), p.540-550

Ort / Verlag

England: John Wiley and Sons Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Aims In this study the influence of first‐line antimalarial drug artemether‐lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV‐infected Nigerian patients. Methods This was a two‐period, single sequence crossover study. In stage 1, 150 HIV‐infected patients receiving nevirapine‐based antiretroviral regimens were enrolled and genotyped for seven SNPs. Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration. Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs. Intensive sampling was conducted in selected patients from each group. In stage 2, patients received standard artemether‐lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3. Results No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0.80–1.25 no‐effect boundaries. However, the number of patients with trough plasma nevirapine concentration below the 3400 ng ml−1 minimum effective concentration increased from 10% without artemether‐lumefantrine (all extensive metabolizers) to 21% with artemether‐lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers). Conclusions This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co‐administered with artemether‐lumefantrine.